A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics
Carla Casulo, Julie M. Vose, William Y. Ho, Brad Kahl, Mark Brunvand, Andre Goy, Yvette Kasamon, Bruce Cheson, Jonathan W. Friedberg
Dive into the research topics of 'A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics'. Together they form a unique fingerprint.